日本

Publications

Natural killer cells as a potential biomarker for predicting immunotherapy efficacy in patients with non-small cell lung cancer

Cho, Y-H., Choi, M. G., Kim, D. H.

Background: Immunotherapy with immune checkpoint inhibitors for non-small cell lung cancer (NSCLC) has emerged as an important treatment option. Although immunotherapy may significantly improve survival and quality of life, response rates are as low as 20% in NSCLC patients.

Objective: The identification of reliable biomarkers predicting response to immunotherapy is required urgently to determine patient selection guidelines

Citation

Cho, Y-H., Choi, M. G., Kim, D. H. "Natural killer cells as a potential biomarker for predicting immunotherapy efficacy in patients with non-small cell lung cancer" Targeted Oncology (2020): 241–7